Tag Archives: medical

Is Europe equipped with enough medical oncologists? Horizon still unknown

But the society has also warned that a worrying lack of information about the situation in Eastern Europe must be urgently addressed. Published in the Annals of Oncology this week, the survey provides the first detailed information on the current number of medical oncologists in 12 European Union countries, mostly in Western Europe, and their predicted availability by 2020. Around the world countries are struggling to ensure their medical oncology systems can deal with the increase in cancer cases, says ESMO Press Officer Solange Peters, a lung cancer expert from the university of Lausanne, Switzerland. Until now, nobody could say what the situation was in Europe. …

T-cell research sheds light on why HIV can persist despite treatment

The paper, titled "HIV-1 Persistence in CD4+ T-Cells with Stem Cell-Like Properties," provides evidence that a particular T-cell type may help researchers better understand why HIV can persist despite treatment. Zurakowski’s co-authors include Mathias Lichterfeld, the paper’s lead author, and researchers from Massachusetts General Hospital (MGH); Ragon Institute of MGH, the Massachusetts Institute of Technology and Harvard University; the First Affiliated Hospital of China Medical University; Brigham and Women’s Hospital; and Howard Hughes Medical Institute. Zurakowski explained that HIV treatments do not kill infected cells…

Study identifies population of stem-like cells where HIV persists in spite of treatment

"Most human cells are short lived, so it has been unclear how HIV manages to stick around for decades in spite of very effective antiviral treatment," says Mathias Lichterfeld, MD, of the MGH Infectious Disease Division, corresponding author of the report receiving advance online publication in Nature Medicine. "This question led to the hypothesis that HIV might infect stem cells — the most long-lasting cells in the body — but traditional organ-specific stem cells, even those that give rise to all immune and blood cells, are resistant to HIV infection. We have discovered that a new group of T cells, called T memory stem cells, are susceptible to HIV and likely represent the longest lasting cellular niche for the virus." HIV has such a devastating impact on the human immune system because it infects the CD4-positive T cells that normally direct and support the infection-fighting activities of other immune cells. Several subtypes of CD4 T cells have different functions; and all are capable of being infected by HIV, although antiviral treatment keeps the virus in those cells from replicating…

Epigenetics of breast cancer family history

Researchers from the Columbia University Medical Center in New York have now examined whether a specific epigenetic modification (more specifically, methylation of the DNA) can be associated to breast cancer family history in unaffected women from high-risk breast cancer families. This important work suggests that the levels of DNA methylation in white blood cells from cancer-free women could be one of the factors playing a role in the clustering of breast cancer in families with extensive cancer histories within its members. source : http://www.sciencedaily.com/releases/2014/01/140107172017.htm

Novel non-invasive therapy prevents breast cancer formation in mice

The therapy emerged from a sophisticated effort to reverse-engineer gene networks to identify genes that drive cancer. The same strategy could lead to many new therapies that disable cancer-causing genes no current drugs can stop, and it also can be used to find therapies for other diseases…

Technologies revealed that streamline breast cancer treatment

Jersey Shore and Ocean Medical Center now offer accelerated partial breast irradiation (APBI) for breast cancer treatment using the CONTURA ® Multi-Lumen Balloon (MLB) Catheter. This unique method of radiation treatment delivery involves the placement of a deflated balloon in the lumpectomy cavity post-surgery through a small incision. The balloon is then filled with saline and temporarily left in place for up to 10 days during treatment. …

Freezing semen doubles chances of fatherhood for men after treatment for Hodgkin lymphoma

In the first study to investigate the impact on fatherhood of freezing semen prior to cancer treatment, researchers questioned 902 male survivors of Hodgkin lymphoma in five European countries (France, Belgium, The Netherlands, Italy and Switzerland) and found that among the 334 who wanted to have children, the availability of frozen semen doubled their chances of doing so when compared with men who had not frozen their semen. Dr Marleen van der Kaaij (MD), who carried out the work while she was a PhD student at the University Medical Centre in Groningen (The Netherlands), said: "Our study shows that cryopreservation of semen before cancer treatment has a large impact: one in five children born after Hodgkin lymphoma treatment was born using cryopreserved semen. …

Deep sequencing of breast cancer tumors predict outcomes after single dose of therapy

Results showed that through deep genome sequencing, a reduction in the most commonly mutated genes in breast cancer could be observed after just one dose of preoperative therapy. Deep sequencing is a process that involves sequencing the same region multiple times to identify mutations within tumors that have an importance in cancer evolution. These new findings were presented during the 2013 San Antonio Breast Cancer Symposium. "Genomics is the new frontier of cancer research, and this study shows that we may be able to accurately determine what treatment methods will and will not be effective for individual patients after just one dose of medicine," said Lyndsay Harris, MD, study investigator and Director, Breast Cancer Program, UH Seidman Cancer Center and Professor of Medicine at Case Western Reserve University School of Medicine. …

Herceptin plus taxol highly effective in low-risk breast cancer

The study is the first major trial to examine the Herceptin-Taxol combination in patients who have a type of breast cancer with the biology known as small, node-negative, HER2+. Results were presented during the 2013 San Antonio Breast Cancer Symposium. "This is great news for patients and their physicians," said Kathy Albain, MD, of Loyola University Medical Center, who is one of the co-authors of the national multicenter study. "This study identifies a new treatment option for this population of patients that is highly effective and has minimal side effects." First author is Sara Tolaney, MD, of the Dana-Farber Cancer Institute…